Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes
about
A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccineTowards a rational design of an asymptomatic clinical herpes vaccine: the old, the new, and the unknownHerpes simplex virus 2 ICP0 mutant viruses are avirulent and immunogenic: implications for a genital herpes vaccineHSV-2: in pursuit of a vaccineProphylactic human papillomavirus vaccinesRandomized controlled trials of interventions to prevent sexually transmitted infections: learning from the past to plan for the future.A pooled analysis of the effect of condoms in preventing HSV-2 acquisitionBlocking antibody access to neutralizing domains on glycoproteins involved in entry as a novel mechanism of immune evasion by herpes simplex virus type 1 glycoproteins C and EIncrease in rates of herpes simplex virus type 1 as a cause of anogenital herpes in western Sydney, Australia, between 1979 and 2003Prevalence of infection with herpes simplex virus types 1 and 2 in Australia: a nationwide population based surveySeroepidemiology of Herpes Simplex virus type 1 and 2 in Western and Southern Switzerland in adults aged 25-74 in 1992-93: a population-based studyPrevention of genital herpes in a guinea pig model using a glycoprotein D-specific single chain antibody as a microbicideUnderstanding natural herpes simplex virus immunity to inform next-generation vaccine designOptimal management of genital herpes: current perspectivesToll-like receptors: the swiss army knife of immunity and vaccine developmentInfectious co-factors in HIV-1 transmission herpes simplex virus type-2 and HIV-1: new insights and interventionsTissue-resident memory T cellsBovine Herpes Virus 1 (BHV-1) and Herpes Simplex Virus Type 1 (HSV-1) Promote Survival of Latently Infected Sensory Neurons, in Part by Inhibiting ApoptosisImmune regulation of human herpesviruses and its implications for human transplantationThe challenges and opportunities for the development of a T-cell epitope-based herpes simplex vaccineMathematical Modeling Predicts that Increased HSV-2 Shedding in HIV-1 Infected Persons Is Due to Poor Immunologic Control in Ganglia and Genital MucosaPhase I Dose-Escalation Study of a Monovalent Heat Shock Protein 70-Herpes Simplex Virus Type 2 (HSV-2) Peptide-Based Vaccine Designed To Prime or Boost CD8 T-Cell Responses in HSV-Naive and HSV-2-Infected SubjectsViral infections of the fetus and newborn infantImmune Adjuvant Effect of Molecularly-defined Toll-Like Receptor LigandsGenital Herpes: Insights into Sexually Transmitted Infectious DiseaseNovel agents and strategies to treat herpes simplex virus infections.Agents and strategies in development for improved management of herpes simplex virus infection and disease.Gender differences in clinical presentation and outcomes of epidemic Kaposi sarcoma in Uganda.HIV-1/HSV-2 co-infected adults in early HIV-1 infection have elevated CD4+ T cell counts.Genital herpes.New concepts in understanding genital herpes.Immunization with a dominant-negative recombinant Herpes Simplex Virus (HSV) type 1 protects against HSV-2 genital disease in guinea pigs.The herpevac trial for women: Sequence analysis of glycoproteins from viruses obtained from infected subjects.Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative womenLiposomal gD ectodomain (gD1-306) vaccine protects against HSV2 genital or rectal infection of female and male mice.Mucosal treatments for herpes simplex virus: insights on targeted immunoprophylaxis and therapyHerpes simplex virus type 2 vaccines: new ground for optimism?Construction and properties of a herpes simplex virus 2 dl5-29 vaccine candidate strain encoding an HSV-1 virion host shutoff protein.Asymptomatic HLA-A*02:01-restricted epitopes from herpes simplex virus glycoprotein B preferentially recall polyfunctional CD8+ T cells from seropositive asymptomatic individuals and protect HLA transgenic mice against ocular herpes.Population level impact of an imperfect prophylactic vaccine for herpes simplex virus-2
P2860
Q21089976-8BF00086-F702-4C52-ADCE-9303B6441B1CQ21296712-EE0B35FE-9827-4197-81FE-8E0F87DFEBF9Q21562177-30B5EF88-C220-416F-80F8-0735E0DCBE6AQ22306291-8923E05A-E0DF-4E11-BD19-F5394BB4458EQ24545449-AC3DA450-5687-4EEA-86BB-6CBA760FF1ECQ24600011-52AB8A56-ADBC-4D71-BEEB-F7FA1A69EDDFQ24631935-E2551BC2-A8EB-4AAB-8A58-973B89771B5AQ24646778-AC7882E3-0F1A-44FD-8C1D-40E96141D420Q24654682-28202CCF-CF3F-4841-B790-41F4A851B3D3Q24654706-1877EC0B-F586-4517-858C-F20A77207657Q24791873-9F3BC558-2501-474A-A2AA-4AE387C56914Q24803342-0C014892-7BE1-47EC-A339-4424B503F3A2Q26741484-7AE895B6-179C-4DDE-8B68-3C018DF6650DQ26746041-0B58C9AC-4F9D-428E-8F24-458BEF2BDACBQ26746644-F73D6474-8C89-4379-A22A-E6DA6134FE53Q26823594-AEA2AC3A-0761-40D1-A7A1-81493CB72970Q26829804-EB7C3DB1-6BF6-4220-88D4-D38751E88DABQ26864175-000EEFCB-1106-4ABF-B864-FB6AB660D74BQ26992146-AD70FCFA-A0DF-4511-8D09-ADDDDDDCAF6DQ27021292-B1DDCF9F-CC3C-4CC1-9A36-8A75EC4DBF9BQ27347896-7020BBA8-7893-4152-9DA1-58D6742EBEE0Q27486108-D3BD26D6-4985-4F3A-8296-87D09E7E9DCCQ27488781-4D194D77-6D4C-4D7A-9BE1-EDF9B2240268Q28972540-8A2C6F85-FF80-4460-A414-A3D94C30E8F9Q30235026-D00FE991-1DC3-42B8-97DD-4ABB578483B0Q30332444-DDEE4C69-813A-4E16-B7D4-C25FFE28454BQ30350341-4FAA20FC-362E-450F-BBFF-82C237DF0238Q30396626-094DF143-1CF9-4A19-9843-E1DB718E9B37Q33303686-D9509696-621C-4010-8668-CB49DE314716Q33448071-7E513644-A7FD-48A1-8796-EDC6DF938A14Q33582145-626974B8-BA15-4231-8F90-8470F241E6B8Q33595097-F1BFD0C7-0F5A-4C3E-B26F-B02047C5416CQ33610941-E9F8FADD-D256-4B05-9CDD-7F28C76D9161Q33663463-A199987B-695E-4845-AFAD-7CBAA7794FC4Q33668447-8238DE6E-82E1-4056-8D9D-DE6D6280E267Q33710019-CE50F28A-A588-48DB-809A-116A6CADBC19Q33711912-B281A63E-11FC-456B-843B-98420D612ACEQ33724497-9E317658-7758-43C8-8CED-196416EDD8A7Q33755236-31853753-1198-4C53-9DC5-C50878CF7DAFQ33812029-87B20BD8-AF0F-4829-96FC-60D3F5426868
P2860
Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes
description
im November 2002 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 November 2002
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в листопаді 2002
@uk
name
Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes
@en
Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes
@nl
type
label
Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes
@en
Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes
@nl
prefLabel
Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes
@en
Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes
@nl
P2093
P50
P356
P1476
Glycoprotein-D-adjuvant vaccine to prevent genital herpes
@en
P2093
David I Bernstein
Fred Y Aoki
Gary Dubin
GlaxoSmithKline Herpes Vaccine Efficacy Study Group
Lawrence R Stanberry
Martine Denis
Pierre Vandepapeliere
Spotswood L Spruance
Stephen Sacks
Stephen Tyring
P304
P356
10.1056/NEJMOA011915
P407
P577
2002-11-01T00:00:00Z